Clinical Trial

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-01.
Status change: Not Yet Recruiting → Recruiting 2025-01-05
Trial Details
NCT Number NCT06584032
Lead Sponsor Hutchmed
Conditions Advanced Endometrial Cancer
Enrollment 412 participants
Start Date 2024-12-12
Primary Completion 2029-01-08 (estimated)
Study Completion 2029-06-09 (estimated)
Updated on ClinicalTrials.gov 2025-01-07